Although our transcriptomic and bioinformatic findings are consistent with existing literature on the role of palmitoylation in cancer, additional in vitro and in vivo experiments are necessary to identify the specific substrates of ZDHHC18 in ccRCC and to elucidate their involvement in tumor progression, immune evasion, and therapy resistance. This evidence concerns the gene ZDHHC18 and nonpapillary renal cell carcinoma.